性腺刺激ホルモン放出ホルモン（Gonadotropin releasing hormone, GnRH）はFSHとLHを下垂体前葉から分泌させるペプチドホルモンである。これは視床下部で合成、分泌される。
目次
- 1 遺伝子
- 2 構造
- 3 神経ホルモンとしてのGnRH
- 4 FSHとLHのコントロール
- 5 活性
- 6 他の器官でのGnRH
- 7 処方
- 8 アゴニスト（作用薬）とアンタゴニスト（拮抗薬）
遺伝子
GnRH前駆体の遺伝子は第8番染色体に位置する。この前駆体は92のアミノ酸からなり、デカペプチド（10のアミノ酸）のGnRHへ加工される。
構造
GnRHの姿は1977年ノーベル賞受賞者のロジェ・ギルマンとアンドリュー・ウィクター・シャリーにより次の様に明らかにされた：pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly CONH2.
神経ホルモンとしてのGnRH
GnRHは特定の神経細胞で産生され、その神経末端から放出される神経ホルモンと考えられている。視床下部のGnRHの産生の主要エリアは視索前野で、そこに殆どのGnRH分泌ニューロンが含まれている。GnRHは正中隆起の高さで門脈血流へ分泌され、性腺刺激ホルモン産生細胞の膜上にある受容体を活性化させる。GnRHはタンパク質分解によって数分の内に分解される。
FSHとLHのコントロール
下垂体ではGnRHはFSHとLHの合成と分泌を刺激し、その過程はGnRHパルスの頻度と強さ、それからアンドロゲンとエストロゲンのフィードバックである。GnRH分泌には性差が存在し、男性ではGnRHは一定の頻度で分泌されるのに対し、女性では月経周期によってその頻度が異なり、排卵前にGnRHが急激に高まる。GnRHの拍動性は全ての脊椎動物において見られ、正しい生殖機能を確実にするのに不可欠である。従って雌ではホルモンであるGnRHが単独で卵胞成長、排卵、黄体の保持という複合した過程、そして雄では精子形成をコントロールする。
活性
GnRHの活性は子供のうちは非常に低い。繁殖年齢ではパルス活性は複数のフィードバックによりコントロールされた順調な繁殖機能へ重大な意味をもつ。しかしながら、妊娠するとGnRH活性は要求されなくなる。パルス活性は視床下部・下垂体どちらかでの不全（即ち視床下部抑制）または器官の傷害（外傷、腫瘍）により乱される。プロラクチンの上昇によりGnRH活性は低下する。対照的に高インスリン血症ではパルス活性を上昇させ、多嚢胞性卵巣症候群（PCOS）で見られる様なLHとFSHの活性の障害へ導く。GnRHの形成はカルマン症候群では先天的に存在しない。ドーパミンはGnRH活性を低下させるらしい。
他の器官でのGnRH
GnRHは視床下部と下垂体以外の例えば胎盤や性腺にも見られ、そこでの役割はよく判っていない。
処方
GnRHはゴナドレリン塩酸塩（Factrel）として注射して使われる。研究によって、これが注入ポンプシステムを通して視床下部性性腺機能低下症の患者へ排卵を誘発させる事が明らかになった。
アゴニスト（作用薬）とアンタゴニスト（拮抗薬）
GnRHが合成され手に入るようになった一方で、短い半減期の所為でそれを医療へ用いるには注入ポンプを要する。GnRHのデカペプチド構造の改変により性腺刺激ホルモンへ刺激（GnRHアゴニスト）または抑制（GnRHアンタゴニスト）の作用をする類似体の薬物に行き着いた。重要なことに、ダウンレギュレーションを通してアゴニストはまた延長された抑制効果を行使することができる。
|
内分泌器：ホルモン（ペプチドホルモン、ステロイドホルモン） |
|
| 視床下部 - 脳下垂体 |
|
視床下部
|
GnRH - TRH - ドーパミン - CRH - GHRH - ソマトスタチン - ORX - MCH - MRH - MIH
|
|
|
脳下垂体後葉
|
バソプレッシン - OXT
|
|
|
脳下垂体中葉
|
MSH(インテルメジン)
|
|
|
脳下垂体前葉
|
αサブユニット糖タンパク質ホルモン（FSH - LH - TSH） - GH - PRL - POMC（ACTH - エンドルフィン - リポトロピン）
|
|
|
| 副腎 |
|
副腎髄質
|
副腎髄質ホルモン（アドレナリン - ノルアドレナリン - ドーパミン）
|
|
|
副腎皮質
|
副腎皮質ホルモン（アルドステロン - コルチゾール - DHEA）
|
|
|
| 甲状腺 |
|
甲状腺
|
甲状腺ホルモン（T3 - T4 - カルシトニン）
|
|
|
副甲状腺
|
PTH
|
|
|
| 生殖腺 |
|
精巣
|
テストステロン - AMH - インヒビン
|
|
|
卵巣
|
エストラジオール - プロゲステロン - インヒビン/アクチビン - リラキシン（妊娠時）
|
|
|
| その他の内分泌器 |
|
膵臓
|
グルカゴン - インスリン - ソマトスタチン
|
|
|
松果体
|
メラトニン
|
|
|
| 内分泌器でない器官 |
胎盤：hCG - HPL - エストロゲン - プロゲステロン - 腎臓：レニン - EPO - カルシトリオール - プロスタグランジン - 心臓：ANP - BNP - ET - 胃：ガストリン - グレリン - 十二指腸：CCK - GIP - セクレチン - モチリン - VIP - 回腸：エンテログルカゴン - 脂肪組織：レプチン - アディポネクチン - レジスチン - 胸腺：サイモシン - サイモポイエチン - サイムリン - STF - THF - 肝臓：IGFs（IGF-1 - IGF-2） - 耳下腺：バロチン - 末梢神経系：CGRP - P物質
|
|
| 誘導タンパク質 |
NGF - BDNF - NT-3
|
|
| Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) |
from PDB 1YY1 |
| Identifiers |
| Symbols |
GNRH1 ; GNRH; GRH; HH12; LHRH; LNRH |
| External IDs |
OMIM: 152760 MGI: 95789 HomoloGene: 641 GeneCards: GNRH1 Gene |
| Gene ontology |
| Molecular function |
• hormone activity
• gonadotropin hormone-releasing hormone activity
|
| Cellular component |
• extracellular region
• extracellular space
|
| Biological process |
• signal transduction
• cell-cell signaling
• multicellular organismal development
• female pregnancy
• negative regulation of cell proliferation
• regulation of gene expression
• response to corticosteroid
• ovulation cycle
• negative regulation of apoptotic process
• response to ethanol
• regulation of ovarian follicle development
• negative regulation of neuron migration
|
| Sources: Amigo / QuickGO |
|
| RNA expression pattern |
|
| More reference expression data |
| Orthologs |
| Species |
Human |
Mouse |
|
| Entrez |
2796 |
14714 |
|
| Ensembl |
ENSG00000147437 |
ENSMUSG00000015812 |
|
| UniProt |
P01148 |
P13562 |
|
| RefSeq (mRNA) |
NM_000825 |
NM_008145 |
|
| RefSeq (protein) |
NP_000816 |
NP_032171 |
|
| Location (UCSC) |
Chr 8:
25.28 – 25.28 Mb |
Chr 14:
67.75 – 67.75 Mb |
|
| PubMed search |
[1] |
[2] |
|
|
|
|
|
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2013) |
Gonadotropin-releasing hormone (GnRH), also known as Luteinizing-hormone-releasing hormone (LHRH) and luliberin, is a trophic peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released from GnRH neurons within the hypothalamus. The peptide belongs to gonadotropin-releasing hormone family. It constitutes the initial step in the hypothalamic–pituitary–gonadal axis.
Contents
- 1 Production
- 2 Structure
- 3 Neurohormone
- 4 Control of FSH and LH
- 5 Activity
- 6 Other organs
- 7 Effects of behavior
- 8 Animal sexual behavior
- 9 Medical uses
- 10 Agonists and antagonists
- 11 References
- 12 Further reading
Production
The gene, GNRH1, for the GnRH precursor is located on chromosome 8. In mammals, the linear decapeptide end-product is synthesized from a 92-amino acid preprohormone in the preoptic anterior hypothalamus. It is the target of various regulatory mechanisms of the hypothalamic–pituitary–gonadal axis, such as being inhibited by increased estrogen levels in the body.
Structure
The identity of GnRH was clarified by the 1977 Nobel Laureates Roger Guillemin and Andrew V. Schally:
pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
As is standard for peptide representation, the sequence is given from amino terminus to carboxyl terminus; also standard is omission of the designation of chirality, with assumption that all amino acids are in their L- form. The abbreviations appearing are to standard proteinogenic amino acids, except for pyroGlu, which refers to pyroglutamic acid, a derivative of glutamic acid. The NH2 at the carboxyl terminus indicates that rather than terminating as a free carboxylate, it terminates as a carboxamide.
Neurohormone
GnRH is considered a neurohormone, a hormone produced in a specific neural cell and released at its neural terminal. A key area for production of GNRH is the preoptic area of the hypothalamus, which contains most of the GnRH-secreting neurons. GnRH neurons originate in the nose and migrate into the brain, where they are scattered throughout the medial septum and hypothalamus and connected by very long >1-millimeter-long dendrites. These bundle together so they receive shared synaptic input, a process that allows them to synchronize their GnRH release.[1]
GnRH is secreted in the hypophysial portal bloodstream at the median eminence. The portal blood carries the GnRH to the pituitary gland, which contains the gonadotrope cells, where GnRH activates its own receptor, gonadotropin-releasing hormone receptor (GnRHR), a seven-transmembrane G-protein-coupled receptor that stimulates the beta isoform of Phosphoinositide phospholipase C, which goes on to mobilize calcium and protein kinase C. This results in the activation of proteins involved in the synthesis and secretion of the gonadotropins LH and FSH. GnRH is degraded by proteolysis within a few minutes.
Control of FSH and LH
At the pituitary, GnRH stimulates the synthesis and secretion of the gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). These processes are controlled by the size and frequency of GnRH pulses, as well as by feedback from androgens and estrogens. Low-frequency GnRH pulses lead to FSH release, whereas high-frequency GnRH pulses stimulate LH release.[2]
There are differences in GnRH secretion between females and males. In males, GnRH is secreted in pulses at a constant frequency; however, in females, the frequency of the pulses varies during the menstrual cycle, and there is a large surge of GnRH just before ovulation.[citation needed]
GnRH secretion is pulsatile in all vertebrates [there is no evidence that this is correct -- the only empirical evidence to date is for a handful of mammals], and is necessary for correct reproductive function. Thus, a single hormone, GnRH1, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male.
Activity
GnRH activity is very low during childhood, and is activated at puberty or adolescence. During the reproductive years, pulse activity is critical for successful reproductive function as controlled by feedback loops. However, once a pregnancy is established, GnRH activity is not required. Pulsatile activity can be disrupted by hypothalamic-pituitary disease, either dysfunction (i.e., hypothalamic suppression) or organic lesions (trauma, tumor). Elevated prolactin levels decrease GnRH activity. In contrast, hyperinsulinemia increases pulse activity leading to disorderly LH and FSH activity, as seen in polycystic ovary syndrome (PCOS). GnRH formation is congenitally absent in Kallmann syndrome.
The GnRH neurons are regulated by many different afferent neurons, using several different transmitters (including norepinephrine, GABA, glutamate). For instance, dopamine appears to stimulate LH release (through GnRH) in estrogen-progesterone-primed females; dopamine may inhibit LH release in ovariectomized females.[3] Kisspeptin appears to be an important regulator of GnRH release.[4] GnRH release can also be regulated by estrogen. It has been reported that there are kisspeptin-producing neurons that also express estrogen receptor alpha.[5]
Other organs
GnRH is found in organs outside of the hypothalamus and pituitary, and its role in other life processes is poorly understood. For instance, there is likely to be a role for GnRH1 in the placenta and in the gonads. GnRH and GnRH receptors are also found in cancers of the breast, ovary, prostate, and endometrium.[6]
Effects of behavior
GnRH production/release is one of the few confirmed examples of behavior influencing hormones, rather than the other way around.[citation needed] Cichlid fish that become socially dominant in turn experience an upregulation of GnRH secretion whereas cichlid fish that are socially subordinate have a down regulation of GnRH secretion.[7] Besides secretion, the social environment as well as their behavior affects the size of GnRH neurons. Specifically, males that are more territorial have larger GnRH neurons than males that are less territorial males. Differences are also seen in females, with breeding females having smaller GnRH neurons than controls females.[8] These examples suggest that GnRH is a socially regulated hormone.
Animal sexual behavior
GnRH activity influences a variety of sexual behaviors. Increased levels of GnRH facilitate sexual displays and behavior in females. GnRH injections enhance copulation solicitation (a type of courtship display) in white-crowned sparrows.[9] In mammals, GnRH injections facilitate sexual behavior of female display behaviors as shown with the musk shrew’s (Suncus murinus) reduced latency in displaying rump presents and tail wagging towards males.[10]
An elevation of GnRH raises males’ testosterone capacity beyond a male’s natural testosterone level. Injections of GnRH in male birds immediately after an aggressive territorial encounter results in higher testosterone levels than what is observed naturally during an aggressive territorial encounter.[11]
A compromised GnRH system has aversive effects on reproductive physiology and maternal behavior. In comparison to female mice with a normal GnRH system, female mice with a 30% decrease in GnRH neurons are poor caregivers to their offspring. These mice are more likely to leave their pups scattered rather than grouped together, and will take significantly longer to retrieve their pups.[12]
Medical uses
GnRH is available as gonadorelin hydrochloride (Factrel®) and gonadorelin diacetate tetrahydrate (Cystorelin®) for injectable use. It has a chemical composition and structure identical to the natural hormone, identified from porcine or ovine hypothalami. It is currently used for evaluating hypothalamic-pituitary gonadotropic function. Studies have described it being used via an infusion pump system to induce ovulation in patients with hypothalamic hypogonadism.
It is also used in veterinary medicine as a treatment for cattle with cystic ovarian disease.
Its analogue Leuprolide is used for continuous infusion, to treat Breast carcinoma, endometriosis, prostate carcinoma, and following research in the 1980s by researchers, including Dr. Florence Comite of Yale University, it was used to treat precocious puberty.[13][14] The analogue Deslorelin is used in veterinary reproductive control through a sustained-release implant.
Agonists and antagonists
While GnRH has been synthesized and become available, its short half-life requires infusion pumps for its clinical use. Modifications of the decapeptide structure of GnRH have led to GnRH1 analog medications that either stimulate (GnRH1 agonists) or suppress (GnRH antagonists) the gonadotropins. It is important to note that, through downregulation, agonists are also able to exert a prolonged suppression effect.
References
- ^ Campbell RE, Gaidamaka G, Han SK, Herbison AE (June 2009). "Dendro-dendritic bundling and shared synapses between gonadotropin-releasing hormone neurons". Proc. Natl. Acad. Sci. U.S.A. 106 (26): 10835–40. doi:10.1073/pnas.0903463106. PMC 2705602. PMID 19541658.
- ^ Jayes, Friederike C. Lking; Jack H. Britt and Kenneth L. Esbenshade (1997). "Role of Gonadotropin-Releasing Hormone Pulse Frequency in Differential Regulation of Gonadotropins in the Gilt". Biology of Reproduction 56: 1012-1019. doi:10.1095/biolreprod56.4.1012. Retrieved 25 November 2013.
- ^ Brown RM (1994). An introduction to Neuroendocrinology. Cambridge, UK: Cambridge University Press. ISBN 0-521-42665-0.
- ^ Dungan HM, Clifton DK, Steiner RA (March 2006). "Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion". Endocrinology 147 (3): 1154–8. doi:10.1210/en.2005-1282. PMID 16373418.
- ^ Franceschini I, Lomet D, Cateau M, Delsol G, Tillet Y, Caraty A (July 2006). "Kisspeptin immunoreactive cells of the ovine preoptic area and arcuate nucleus co-express estrogen receptor alpha". Neurosci. Lett. 401 (3): 225–30. doi:10.1016/j.neulet.2006.03.039. PMID 16621281.
- ^ Schally AV (1999). "Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis.". Peptides 20 (10): 1247–62. doi:10.1016/S0196-9781(99)00130-8. PMID 10573298.
- ^ Chee SS, Espinoza WA, Iwaniuk AN, Pakan JM, Gutiérrez-Ibáñez C, Wylie DR, Hurd PL (January 2013). "Social status, breeding state, and GnRH soma size in convict cichlids (Cryptoheros nigrofasciatus)". Behav. Brain Res. 237: 318–24. doi:10.1016/j.bbr.2012.09.023. PMID 23000535.
- ^ White SA, Nguyen T, Fernald RD (September 2002). "Social regulation of gonadotropin-releasing hormone". J. Exp. Biol. 205 (Pt 17): 2567–81. PMID 12151363.
- ^ Maney DL, Richardson RD, Wingfield JC (August 1997). "Central administration of chicken gonadotropin-releasing hormone-II enhances courtship behavior in a female sparrow". Horm Behav 32 (1): 11–8. doi:10.1006/hbeh.1997.1399. PMID 9344687.
- ^ Schiml PA, Rissman EF (May 2000). "Effects of gonadotropin-releasing hormones, corticotropin-releasing hormone, and vasopressin on female sexual behavior". Horm Behav 37 (3): 212–20. doi:10.1006/hbeh.2000.1575. PMID 10868484.
- ^ DeVries MS, Winters CP, Jawor JM (June 2012). "Testosterone elevation and response to gonadotropin-releasing hormone challenge by male northern cardinals (Cardinalis cardinalis) following aggressive behavior". Horm Behav 62 (1): 99–105. doi:10.1016/j.yhbeh.2012.05.008. PMID 22613708.
- ^ Brooks LR, Le CD, Chung WC, Tsai PS (2012). "Maternal behavior in transgenic mice with reduced fibroblast growth factor receptor function in gonadotropin-releasing hormone neurons". Behav Brain Funct 8: 47. doi:10.1186/1744-9081-8-47. PMC 3503805. PMID 22950531.
- ^ Comite F, Cutler GB, Rivier J, Vale WW, Loriaux DL, Crowley WF (24 December 1981). "Short-Term Treatment of Idiopathic Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing Hormone". New England Journal of Medicine 305 (26): 1546–1550. doi:10.1056/NEJM198112243052602. PMID 6458765.
- ^ Sonis WA, Comite F, Pescovitz OH, Hench K, Rahn CW, Cutler GB, Loriaux DL, Klein RP (1986 r). "Biobehavioral aspects of precocious puberty". J Am Acad Child Psychiatry 25 (5): 674–9. doi:10.1016/S0002-7138(09)60293-4. PMID 3760417.
Further reading
- Flanagan CA, Millar RP, Illing N (1998). "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions". Rev. Reprod. 2 (2): 113–20. doi:10.1530/ror.0.0020113. PMID 9414473.
- Leung PC, Cheng CK, Zhu XM (2004). "Multi-factorial role of GnRH-I and GnRH-II in the human ovary". Mol. Cell. Endocrinol. 202 (1–2): 145–53. doi:10.1016/S0303-7207(03)00076-5. PMID 12770744.
- Gründker C, Emons G (2004). "Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer". Reprod. Biol. Endocrinol. 1: 65. doi:10.1186/1477-7827-1-65. PMC 239893. PMID 14594454.
- Limonta P, Moretti RM, Montagnani Marelli M, Motta M (2004). "The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans". Frontiers in neuroendocrinology 24 (4): 279–95. doi:10.1016/j.yfrne.2003.10.003. PMID 14726258.
- Janáky T, Juhász A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Milovanovic S, Redding TW, Rékási Z, Nagy A (1992). "Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups". Proc. Natl. Acad. Sci. U.S.A. 89 (3): 972–6. doi:10.1073/pnas.89.3.972. PMC 48367. PMID 1310542.
- Healey SC, Martin NG, Chenevix-Trench G (1991). "NcoI RFLP of the human LHRH gene on chromosome 8p". Nucleic Acids Res. 19 (21): 6059. doi:10.1093/nar/19.21.6059. PMC 329079. PMID 1682898.
- Williamson P, Lang J, Boyd Y (1992). "The gonadotropin-releasing hormone (Gnrh) gene maps to mouse chromosome 14 and identifies a homologous region on human chromosome 8". Somat. Cell Mol. Genet. 17 (6): 609–15. doi:10.1007/BF01233626. PMID 1767338.
- Hayflick JS, Adelman JP, Seeburg PH (1989). "The complete nucleotide sequence of the human gonadotropin-releasing hormone gene". Nucleic Acids Res. 17 (15): 6403–4. doi:10.1093/nar/17.15.6403. PMC 318303. PMID 2671939.
- Nikolics K, Mason AJ, Szönyi E, Ramachandran J, Seeburg PH (1985). "A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone". Nature 316 (6028): 511–7. doi:10.1038/316511a0. PMID 2863757.
- Adelman JP, Mason AJ, Hayflick JS, Seeburg PH (1986). "Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin release-inhibiting factor in human and rat". Proc. Natl. Acad. Sci. U.S.A. 83 (1): 179–83. doi:10.1073/pnas.83.1.179. PMC 322815. PMID 2867548.
- Yang-Feng TL, Seeburg PH, Francke U (1986). "Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2----p21)". Somat. Cell Mol. Genet. 12 (1): 95–100. doi:10.1007/BF01560732. PMID 3511544.
- Seeburg PH, Adelman JP (1984). "Characterization of cDNA for precursor of human luteinizing hormone releasing hormone". Nature 311 (5987): 666–8. doi:10.1038/311666a0. PMID 6090951.
- Tan L, Rousseau P (1983). "The chemical identity of the immunoreactive LHRH-like peptide biosynthesized in the human placenta". Biochem. Biophys. Res. Commun. 109 (3): 1061–71. doi:10.1016/0006-291X(82)92047-2. PMID 6760865.
- Dong KW, Yu KL, Roberts JL (1994). "Identification of a major up-stream transcription start site for the human progonadotropin-releasing hormone gene used in reproductive tissues and cell lines". Mol. Endocrinol. 7 (12): 1654–66. doi:10.1210/me.7.12.1654. PMID 8145771.
- Kakar SS, Jennes L (1996). "Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues". Cancer Lett. 98 (1): 57–62. doi:10.1016/S0304-3835(06)80010-8. PMID 8529206.
- Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J (1996). "Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent". Proc. Natl. Acad. Sci. U.S.A. 93 (14): 7269–73. doi:10.1073/pnas.93.14.7269. PMC 38972. PMID 8692981.
- Chegini N, Rong H, Dou Q, Kipersztok S, Williams RS (1996). "Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro". J. Clin. Endocrinol. Metab. 81 (9): 3215–21. doi:10.1210/jc.81.9.3215. PMID 8784072.
- Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
- Dong KW, Yu KL, Chen ZG, Chen YD, Roberts JL (1997). "Characterization of multiple promoters directing tissue-specific expression of the human gonadotropin-releasing hormone gene". Endocrinology 138 (7): 2754–62. doi:10.1210/en.138.7.2754. PMID 9202214.
- Twan WH, Hwang JS, Lee YH, Jeng SR, Yueh WS, Tung YH, Wu HF, Dufour S, Chang CF (January 2006). "The presence and ancestral role of gonadotropin-releasing hormone in the reproduction of scleractinian coral, Euphyllia ancora". Endocrinology 147 (1): 397–406. doi:10.1210/en.2005-0584. PMID 16195400.
|
Gonadotropins and GnRH (G03G)
|
|
Gonadotropin
preparations |
|
Gonadotropins
|
- Follicle-stimulating hormone
- Human chorionic gonadotropin
- Luteinizing hormone
- Menotropin
- Urofollitropin
|
|
|
Antigonadotropins
|
- Sex steroids (via negative feedback): Androgens
- Estrogens
- Progestogens
- Steroid synthesis inhibitors: Danazol
- Gestrinone
|
|
|
| GnRH analogues |
|
Agonists
|
- Avorelin
- Buserelin
- Deslorelin
- Gonadorelin
- Goserelin
- Histrelin
- Leuprorelin
- Lutrelin
- Nafarelin
- Peforelin
- Triptorelin
|
|
|
Antagonists
|
- Abarelix
- Cetrorelix
- Degarelix
- Detirelix
- Ganirelix
- Iturelix
- Ozarelix
- Prazarelix
- Ramorelix
- Teverelix
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
- Endocrine system:
- hormones
- Peptide hormones
- Steroid hormones
|
|
Endocrine
glands |
|
Hypothalamic-
pituitary
|
|
Hypothalamus
|
- GnRH
- TRH
- Dopamine
- CRH
- GHRH/Somatostatin
- Melanin concentrating hormone
|
|
|
Posterior pituitary
|
|
|
|
Anterior pituitary
|
- α
- FSH
- FSHB
- LH
- LHB
- TSH
- TSHB
- CGA
- Prolactin
- POMC
- CLIP
- ACTH
- MSH
- Endorphins
- Lipotropin
- GH
|
|
|
|
Adrenal axis
|
|
Adrenal cortex:
|
- aldosterone
- cortisol
- DHEA
|
|
|
Adrenal medulla:
|
- epinephrine
- norepinephrine
|
|
|
|
Thyroid axis
|
|
Thyroid:
|
- thyroid hormone
- calcitonin
|
|
|
Parathyroid:
|
|
|
|
|
Gonadal axis
|
|
Testis::
|
|
|
|
Ovary:
|
- estradiol
- progesterone
- activin and inhibin
- relaxin (pregnancy)
|
|
|
Placenta:
|
- hCG
- HPL
- estrogen
- progesterone
|
|
|
|
Islet–acinar
axis
|
|
Pancreas:
|
- glucagon
- insulin
- amylin
- somatostatin
- pancreatic polypeptide
|
|
|
|
Pineal gland
|
|
|
|
Other
glands |
|
Thymus:
|
- Thymosins
- Thymosin α1
- Beta thymosins
- Thymopoietin
- Thymulin
|
|
|
Digestive system:
|
|
Stomach:
|
|
|
|
Duodenum:
|
- CCK
- Incretins
- secretin
- motilin
- VIP
|
|
|
Ileum:
|
- enteroglucagon
- peptide YY
|
|
|
Liver/other
|
- Insulin-like growth factor
|
|
|
|
Adipose tissue:
|
- leptin
- adiponectin
- resistin
|
|
|
Skeleton::
|
|
|
|
Kidney:
|
- JGA (renin)
- peritubular cells
- calcitriol
- prostaglandin
|
|
|
Heart:
|
|
|
|
|
|
|
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|
|
Peptides: neuropeptides
|
|
| Hormones |
see hormones
|
|
| Opioid peptides |
|
Dynorphins
|
- Big dynorphin
- Dynorphin A
- Dynorphin B
- Leumorphin
|
|
|
Endomorphins
|
- Endomorphin-1
- Endomorphin-2
|
|
|
Endorphins
|
- α-Endorphin
- β-Endorphin
- γ-Endorphin
- α-Neoendorphin
- β-Neoendorphin
|
|
|
Enkephalins
|
- Met-enkephalin
- Leu-enkephalin
|
|
|
Others
|
- Adrenorphin
- Amidorphin
- Nociceptin
- Opiorphin
- Spinorphin
|
|
|
Other
neuropeptides |
|
Kinins
|
- Tachykinins: mammal
- Substance P
- Neurokinin A
- Neurokinin B
- amphibian
|
|
|
Neuromedins
|
|
|
|
Other
|
- Angiotensin
- Bombesin
- Calcitonin gene-related peptide
- Carnosine
- Cocaine and amphetamine regulated transcript
- Delta sleep-inducing peptide
- FMRFamide
- Galanin
- Galanin-like peptide
- Gastrin releasing peptide
- Ghrelin
- Neuropeptide S
- Neuropeptide Y
- Neurophysins
- Neurotensin
- Pancreatic polypeptide
- Pituitary adenylate cyclase activating peptide
- RVD-Hpα
- VGF
|
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
![Untitled Document [www.otago.ac.nz]](https://1mg.info/0/i/p/2102.jpg)